ONCOMINE CHRONIC MYELOID LEUKAEMIA CML PANEL Test
At DNA Labs UAE, we offer the ONCOMINE CHRONIC MYELOID LEUKAEMIA (CML) PANEL Test, a comprehensive diagnostic tool using next-generation sequencing (NGS) technology to detect mutations in genes associated with CML.
Test Components
- ABL1
- ASXL1
- CBL
- DNMT3A
- ETV6
- HRAS
- IDH1
- IDH2
- JAK2
- KIT
- KRAS
- MYC
- MECOM
- NRAS
- RUNX1
- RB1
- SF3B1
- SH2B3
- TP53
- TET2
- WT1
Fusion Genes
- ABL1
- ETV6
- JAK2
- KMT2A
- MECOM
- RUNX1
Test Cost
The cost of the ONCOMINE CHRONIC MYELOID LEUKAEMIA CML PANEL Test is AED 8190.0.
Sample Condition
For this test, we require a minimum of 2 mL whole blood or bone marrow sample in a lavender top (EDTA) tube. The sample should be shipped refrigerated and should not be frozen. Please ensure that the NGS Test Requisition Form is duly filled.
Report Delivery
The sample should be submitted by the 1st or 16th of every month, and the report will be delivered on the 15th or 30th of the same month.
Method
The ONCOMINE CHRONIC MYELOID LEUKAEMIA CML PANEL Test is performed using next-generation sequencing (NGS) technology.
Test Type
This test is specifically designed for the diagnosis of leukemia, particularly chronic myeloid leukemia (CML).
Doctor
This test is recommended to be performed by a hematologist or oncologist.
Test Department
This test is conducted in our Molecular Diagnostics department.
Pre Test Information
It is mandatory to fill the NGS Test Requisition Form before undergoing the ONCOMINE CHRONIC MYELOID LEUKAEMIA CML PANEL Test.
Test Details
The ONCOMINE CHRONIC MYELOID LEUKAEMIA (CML) PANEL Test is a highly accurate and minimally invasive diagnostic tool that provides a comprehensive view of the genetic landscape of a patient’s CML. It detects mutations in 27 genes commonly associated with CML, including BCR-ABL1, JAK2, and TP53.
This test enables clinicians to make more personalized treatment decisions, monitor disease progression, and detect the emergence of new mutations that may impact treatment efficacy. Results are typically available within a few days, allowing for timely intervention and improved patient outcomes in the management of CML.
Test Name | ONCOMINE CHRONIC MYELOID LEUKAEMIA CML PANEL Test |
---|---|
Components | ABL1, ASXL1, CBL, DNMT3A, ETV6, HRAS, IDH1,IDH2, JAK2, KIT, KRAS,MYC, MECOM, NRAS, RUNX1, RB1, SF3B1, SH2B3, TP53, TET2, WT1 FUSION GENE – ABL1, ETV6, JAK2, KMT2A, MECOM, RUNX1 |
Price | 8190.0 AED |
Sample Condition | 3 mL (2 mL min.) whole Blood OR Bone Marrow in 1 Lavender top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled NGS Test Requisition Formis mandatory. |
Report Delivery | Sample by 1st / 16th of every month; Report 15th / 30th of Same month |
Method | NGS |
Test type | Leukemia |
Doctor | Hematologist, Oncologist |
Test Department: | MOLECULAR DIAGNOSTICS |
Pre Test Information | Duly filled NGS Test Requisition Formis mandatory. |
Test Details |
The Oncomine Chronic Myeloid Leukaemia (CML) Panel Test is a diagnostic tool that uses next-generation sequencing (NGS) technology to detect mutations in genes associated with CML. The panel includes 27 genes that are commonly mutated in CML, including BCR-ABL1, JAK2, and TP53. The test is designed to provide clinicians with a comprehensive view of the genetic landscape of a patient’s CML, allowing for more personalized treatment decisions. It can also be used to monitor disease progression and detect the emergence of new mutations that may impact treatment efficacy. The Oncomine CML Panel Test is performed on a small sample of blood or bone marrow, and results are typically available within a few days. It is a minimally invasive and highly accurate diagnostic tool that can help improve patient outcomes in the management of CML. |